A phase 3 clinical trial conducted in South Africa has successfully demonstrated that a six-month, all-oral regimen for rifampicin-resistant tuberculosis (RR-TB) is as effective as the traditional nine-month course. Published in The New England Journal of Medicine in June 2026, the BEAT TB study results have already begun to influence global treatment protocols set by the World Health Organization.
Clinical Efficacy And Inclusive Research
Led by the University of the Witwatersrand, the study enrolled over 400 participants to evaluate a regimen comprising bedaquiline, delamanid, linezolid, and either levofloxacin or clofazimine. Crucially, the trial included pregnant women and children—populations that have been systemically excluded from previous TB research.
What was unusual about this study is it was pragmatic and enrolled a similar population to those who are diagnosed and treated in South Africa,” said Dr. Francesca Conradie, the trial’s lead researcher.
The pragmatic design of the study ensures that the findings are directly applicable to the South African public health sector. By shortening the duration of treatment, clinicians anticipate higher patient adherence and better health outcomes for those battling drug-resistant forms of the disease.
Impact On Global Public Health Guidelines
The transition to a six-month, all-oral regimen marks a significant shift from the prolonged and often toxic treatment schedules that have hindered TB control efforts for decades. Experts note that simplifying the medication process is essential for scaling up effective treatment in resource-constrained environments.
“A regimen that can be used across households and across key populations is much easier to implement in routine care,” Dr. Conradie added. Reflecting on the significance of the work, Dr. Francois Venter stated that the study represents world-class research originating from South African institutions that continues to refine and improve TB care globally.
Healthcare authorities are expected to integrate these findings into updated national TB treatment,, management, and control guidelines to address mortality rates linked to drug-resistant infections.